Description
What is KLOW?
KLOW is a co‑lyophilized four‑peptide research blend combining four well‑characterized peptides in a single vial: KPV, LL‑37‑related or GHK‑Cu (depending on the supplier variant), O… (legacy naming), and other healing‑peptide constituents. The widely used formulation contains: GHK‑Cu (copper tripeptide‑1), KPV (anti‑inflammatory tripeptide of α‑MSH), BPC‑157 (gastric protective 15‑aa peptide), and TB‑500 (Thymosin β4 17‑aa active fragment).
Mechanism of Action — Combined
- GHK‑Cu: Copper delivery; fibroblast activation; collagen, elastin, GAG synthesis; hair follicle anagen; broad gene expression modulation
- KPV: Intracellular NF‑κB inhibition; anti‑inflammatory without melanocortin‑receptor activity; anti‑colitis and anti‑dermatitis activity in preclinical models
- BPC‑157: VEGF‑R2/eNOS upregulation; angiogenesis; gut barrier and tendon/ligament repair
- TB‑500: G‑actin sequestration; cell migration; laminin‑5 upregulation; cardiac and dermal repair
- Rationale: four mechanistically distinct arms of tissue regeneration — matrix synthesis, anti‑inflammation, angiogenesis, and cytoskeletal remodeling
Compound Properties
- Composition: GHK‑Cu + KPV + BPC‑157 + TB‑500 (ratio per lot — confirm via COA)
- Form: Lyophilized powder (blue/violet tint characteristic of Cu coordination)
- Source: Each constituent ≥98% purity by HPLC prior to blending
Research‑Reference Dosing
Published research‑reference ranges (for each constituent; no published blend‑specific pharmacology):
- Pickart et al., Experimental Gerontology (2012, 2015): GHK‑Cu.
- Kannengiesser et al., Inflammatory Bowel Diseases (2008); Dalmasso, Gastroenterology (2008): KPV.
- Sikiric et al., Current Pharmaceutical Design (2010): BPC‑157.
- Malinda, JID (1999); Bock‑Marquette, Nature (2004): TB‑500 / Tβ4.
- No peer‑reviewed clinical trial data exists for this specific four‑peptide blend.
Research Findings
- Each constituent has independent preclinical evidence in its respective tissue‑repair or anti‑inflammatory domain
- Blend‑specific PK and synergy have not been formally characterized
- Common preclinical research protocol for integrated skin, gut, and soft‑tissue regeneration studies
Known Side Effects Reported in Research/Trials
- Injection‑site erythema or mild burning (copper‑peptide characteristic)
- Blue/green solution color from copper coordination is normal
- Theoretical copper overload with prolonged high‑dose use
- Theoretical pro‑angiogenic caution in occult neoplasia (TB‑500/BPC‑157)
- Long‑term human safety data unavailable for any constituent
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
